---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000104"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-09-19T23:59:59+00:00"
generated_at: "2026-05-31T03:40:28.586020+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Autolus Therapeutics appoints Matthias Will, M.D. as Chief Development Officer

## Summary
- Dr. Will joins as CDO effective September 30, 2024.
- Previously CMO at Dren Bio and VP Clinical Development at CRISPR Therapeutics.
- Will lead development organization, including obe-cel for relapsed/refractory adult B-ALL.
- Appointment comes as Autolus prepares to commercialize first product obe-cel.

## SEC filing metadata
- accession: 0001730463-24-000104
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-09-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000104/0001730463-24-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000104/autl-20240913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000104
- JSON: https://secwatch.observer/filing/0001730463-24-000104.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.